IL13 Signaling in Allergic Asthma
Completed · NCT05478824
Conditions: Asthma, Allergic, Asthma, Obesity
At a glance
- Research payments reported, 2025
- $72,199
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- Duke University (with Regeneron Pharmaceuticals)
- Dates
- Started 2023-02-21; completion 2025-11-11
- Results posted
- Not yet
This study will investigate the role of dupilumab in the treatment of asthma with comorbid obesity. It is hypothesized that in airway epithelial cells, unique transcriptomic and proteomic expression patterns distinguish allergic and non-allergic patients with asthma and obesity and drive significant differential responses to dupilumab. It is further hypothesized that dupilumab will increase interleukin-13 receptor alpha 2 (IL-13Rα2) levels and/or signaling activity on airway epithelial cells isolated from allergic asthma patients with obesity. This is a pre-clinical research study of dupilumab-induced gene and protein expression analyses in nasal airway epithelial cells of adults with ast…
From ClinicalTrials.gov, last updated 2026-01-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $72,199 in research payments for this study in 2025 (3 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University $72,199
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.